Skip to main content

Conference Correspondent

Finding Champions
Crystal Dugger suggests why it might be challenging to get key people onboard and suggests how to change that. Read More ›

Keep the Focus on the Patient
Crystal Dugger warns administrators to avoid “scope creep” by having their navigators take on too many tasks; she says the navigator’s focus must always be on the patient. Read More ›

Know Your Worth
Crystal Dugger stresses the necessity of standardizing and quantifying the value of a navigation program to the institution. Read More ›

Traits of a Sustainable Navigation Program
What does it take to sustain a navigation program for years to come? Crystal Dugger lists the most important ones for long-term sustainability. Read More ›

At ASCO 2018, Oncology Practice Management (OPM) discussed the current state of genetics and genomic testing, the increasing understanding of biomarkers, and how they influence the treatment of patients with lung cancer. Read More ›


Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress. Read More ›

At ASCO 2018, Oncology Practice Management (OPM) spoke with Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research at Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT, and David L. Rimm, MD, PhD, Professor of Pathology, Yale University School of Medicine, about the increasing role of biomarkers in the management of patients with lung cancer. Read More ›

Oncology practices, hospitals, and pharmacies are struggling to understand wide variations in the application of sterile compounding and safe handling of oncology hazardous drugs, and the costs and operating burdens of compliance with and adherence to current pharmacy standards. At the 2018 combined meeting of the Association of Community Cancer Centers and the Cancer Center Business Summit, 3 cancer centers shared their stories and experiences related to pharmacy standards compliance. Read More ›


Page 9 of 16